Pace picks up for developing risk stratification technologyApril 1st 2012
The availability of effective treatment for exudative age-related macular degeneration has placed an onus on optometrists to be more aggressive in following AMD patients in order to provide timely referral when anti-VEGF treatment becomes indicated.
P. aeruginosa-Different strains, different therapeutic responsesApril 1st 2012
Recent results from analyses performed by investigators in the Steroids for Corneal Ulcers Trial focusing on patients with Pseudomonas aeruginosa infection showed that, just as in overall study population, adjunctive corticosteroid use did not affect treatment outcomes or safety.
Compliance - priority for patient careJanuary 1st 2012
The prevalence of non-adherence with IOP-lowering medications underscores the need for optometrists to frequently re-assess medication use in glaucoma patients and consider therapies that will enable compliance and prevent it from becoming an efficacy-limiting issue.
Systematic evaluation helps simplify diagnostic challengeSeptember 1st 2011
Understanding the features of the different types of pediatric nystagmus is the basis for determining the etiology of the problem and counseling parents about the need for further evaluation, possible treatments, and their child's prognosis.
Bromfenac yields improvement in visual acuityJuly 1st 2011
Analyses of visual acuity results from phase III clinical trials investigating Q.D. bromfenac sodium ophthalmic solution 0.09% for treatment of inflammation and reduction of pain after cataract surgery show treatment with this nonsteroidal anti-inflammatory drug provides functional benefits in addition to its anti-inflammatory and analgesic effects.
Fixed combination aids drug delivery, enhances ocular surface retentionJuly 1st 2011
A new formulation of a fixed antibiotic/corticosteroid combination containing tobramycin and dexamethasone offers several improved characteristics that make it a viable therapeutic option for management of inflammatory ocular conditions where a risk of bacterial ocular infection exists.
Loteprednol delivers pain reliefJuly 1st 2011
A post hoc analysis of data collected in two published, pivotal clinical trials demonstrates that in addition to its efficacy for treating inflammation following ocular surgery, loteprednol etabonate ophthalmic suspension 0.5% provides statistically significant relief of postoperative pain and other symptoms.
Retinal vein occlusion care center enters new eraApril 1st 2011
Positive results from recent studies evaluating intravitreal steroids and anti-vascular endothelial growth factor agents for the treatment of retinal vein occlusions have resulted in FDA approvals for two products and may be expected to shape a new standard of care for these vision-threatening disorders.